Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 9/20 | 0.55 |
| ▸ | CTSS | P25774 | 6/20 | 0.54 |
| ▸ | CTSL | P07711 | 4/20 | 0.54 |
| ▸ | CTSB | P07858 | 3/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KYNU | Q16719 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704067 | 1.00 | SYK (0.58) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL275394 | 1.00 | SYK (0.58) | SYKCTSKCTSSCTSLCTSB | |
| Hydrochloric Acid SCHEMBL7444521 | 0.99 | SYK (0.57) | SYKCTSKCTSSCTSLCTSB | |
| Hydrochloric Acid SCHEMBL7444525 | 0.99 | SYK (0.57) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL8257062 | 0.90 | PPARA (0.58) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL20885273 | 0.90 | PPARA (0.58) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL11127997 | 0.88 | SYK (0.66) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL21340066 | 0.88 | SYK (0.66) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL19485480 | 0.88 | CTSK (0.62) | SYKCTSKCTSSCTSLCTSB | |
| SCHEMBL6320951 | 0.88 | SYK (0.59) | SYKCTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111171026-B | Production intermediate for nitrogen-containing compound or salt thereof | 富士胶片株式会社 | 2023-03-03 | — | — | CN | disclosed |
| CN-110167933-B | As αVAzole amides and amines as integrin inhibitors | 百时美施贵宝公司 | 2022-06-21 | — | — | CN | disclosed |
| EP-3538527-B1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| US-20210198258-A1 | INTEGRIN ANTAGONISTS | Oxurion NV (BE) | 2021-07-01 | — | — | US | disclosed |
| US-20210015802-A1 | METHOD FOR MANUFACTURING NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF AND MANUFACTURING INTERMEDIATE OF NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2021-01-21 | — | — | US | disclosed |
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | disclosed |
| US-10703752-B2 | Integrin antagonists | Oxurion NV (BE) | 2020-07-07 | — | — | US | disclosed |
| CN-111171026-A | Production intermediate for nitrogen-containing compound or salt thereof | 富士胶片株式会社 | 2020-05-19 | — | — | CN | disclosed |
| CN-107428755-B | Process for producing nitrogen-containing compound or salt thereof, and intermediate for production thereof | 富士胶片株式会社 | 2020-03-03 | — | — | CN | disclosed |
| US-20200055849-A1 | INTEGRIN ANTAGONISTS | Oxurion NV (BE) | 2020-02-20 | — | — | US | disclosed |
| EP-0905139-A2 | 5 ring heterocyles, process for preparation, use as inhibitors of leukocyte adhesion and pharmaceutical preparations comprising them | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-03-31 | — | — | EP | disclosed |
| EP-0903353-A1 | Imidazolidine derivates, their preparation and use, and pharmaceutical compositions containing them | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-03-24 | — | — | EP | disclosed |
| CN-1200374-A | Vitronectin receptor antagonists, their preparation and use | HOECHST AG (DE) | 1998-12-02 | — | — | CN | disclosed |
| EP-0854140-A2 | Vitronectin receptor antagonists, their production and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-22 | — | — | EP | disclosed |
| US-5760028-A | TREATING CANCER METASTASIS, DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, THROMBOSIS, RESTENOSIS, OSTEOPOROSIS, MACULAR DEGENERATION | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-06-02 | — | — | US | disclosed |
| EP-0842943-A2 | 5-Ring heterocycles as inhibitors of leukocyte adhesion and as VLA-4 antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-20 | — | — | EP | disclosed |
| EP-0842944-A2 | Heterocycles as inhibitors of leukocyte adhesion and as antagonists of VLA-4 | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-20 | — | — | EP | disclosed |
| EP-0820988-A2 | Imino derivatives as bone resorption inhibitors and vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-01-28 | — | — | EP | disclosed |
| EP-0820991-A2 | Cycloalkyl derivatives as bone resorption inhibitors and vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-01-28 | — | — | EP | disclosed |
| EP-0796855-A1 | Inhibitors of bone resorption and vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015802-A1 | METHOD FOR MANUFACTURING NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF AND MANUFACTURING INTERMEDIATE OF NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF | C5, C9, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SYK 850/4885CTSK 4281/4885CTSS 4224/4885 |
| US-20210198258-A1 | INTEGRIN ANTAGONISTS | ITGB1, ITGA2B, ITGA1 | SYK 1468/4885CTSK 1824/4885CTSS 2321/4885 |
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | ITGAV, ITGB1, ITGA1 | SYK 525/4885CTSK 2068/4885CTSS 2159/4885 |
| US-10703752-B2 | Integrin antagonists | ITGB1, ITGA2B, ITGA1 | SYK 1442/4885CTSK 2097/4885CTSS 2698/4885 |
| US-20200055849-A1 | INTEGRIN ANTAGONISTS | ITGB1, ITGA2B, ITGA1 | SYK 1442/4885CTSK 2097/4885CTSS 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.